Antidepressant Therapy in Treating Bipolar Type II Major Depression

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare the safety and effectiveness of antidepressant therapy versus mood stabilizing therapy in treating people with bipolar type II major depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antidepressant Therapy for Bipolar II Major Depression

NCT00641927

Bipolar Type II Disorder

COMPLETED PHASE4

Prevention of Relapse & Recurrence of Bipolar Depression

NCT00961961

Bipolar Disorder

COMPLETED PHASE4

Bipolar II Depression: Lithium, SSRI, or the Combination

NCT00276965

Bipolar Disorder Depression

COMPLETED PHASE3

Relapse Prevention for Bipolar Type-II Disorder

NCT00044616

Bipolar Disorder Depression

COMPLETED PHASE4

Acute Treatment of Bipolar II Depression

NCT00074776

Bipolar Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bipolar type II (BP II) depression affects 2.5% of the U.S. adult population. People with BP II disorder do not experience the manic episodes that are characteristic of BP I disorder, but rather they experience more modest mood swings with a greater number of major depressive episodes (MDEs). These MDEs are associated with high rates of disease and death. The treatment of BP II depression remains a challenge for clinicians. Mood stabilizer (MS) monotherapy is the current recommended treatment for BD II MDE, but there is reason to believe that antidepressant drug (AD) monotherapy could also be an effective treatment. However, concerns over AD-induced manic switch episodes have limited the use of this treatment option. Preliminary studies using the ADs fluoxetine or venlafaxine have shown success in treating and lowering the manic switch rate of those with BP II MDE. This study will compare the safety and effectiveness of AD monotherapy versus MS monotherapy in treating people with BP II major depression.

Participation in this double-blind study will last up to 9 months. After screening, which includes a medical and psychiatric history review, a physical exam, an electrocardiogram (EKG) test, clinical laboratory tests, a urine-based drug test, and a pregnancy test if applicable, participants will be randomly placed into one of two treatment groups. Participants in the AD monotherapy group will be treated with venlafaxine, and participants in the MS monotherapy group will be treated with lithium. During the first 12 weeks, there will be a total of nine study visits lasting between 45 and 60 minutes. In these visits, participants will receive their study drug and will undergo various assessments, including a review of medication history and side effects, vital sign measurements, and questionnaires about depression and daily functioning. Blood samples will be taken at most visits.

Participants who respond well during the initial 12 weeks of therapy with either drug will have the option to continue treatment for 6 additional months. During this time, participants will continue their assigned treatment and will attend five monthly study visits that will repeat previous assessments and procedures.

For information on a related study, please follow this link:

http://clinicaltrials.gov/show/NCT00044616

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Disorder Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

I

Antidepressant therapy

Group Type EXPERIMENTAL

Venlafaxine

Intervention Type DRUG

75 to 375 mg

II

Mood stabilizer therapy

Group Type ACTIVE_COMPARATOR

Lithium Carbonate

Intervention Type DRUG

300 to 2400 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Venlafaxine

75 to 375 mg

Intervention Type DRUG

Lithium Carbonate

300 to 2400 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meets DSM-IV criteria for Axis I bipolar II disorder
* Meets DSM-IV criteria for Axis I major depressive episode
* Score of 16 on 17-item HAM-D rating scale
* Not taking monoamine oxidase inhibitors (MAOI) for more than 2 weeks prior to study entry
* Willing to use an effective form of birth control throughout the study

Exclusion Criteria

* History of mania
* Current primary Axis I diagnosis other than bipolar II disorder
* Alcohol or drug dependence within 3 months prior to study entry
* Contraindication to treatment with venlafaxine or lithium
* Unstable medical condition (e.g., thyroid disease, hypertension, or angina pectoris)
* Pregnant or breastfeeding
* Experiencing suicidal thoughts
* Requires hospitalization
* Requires concurrent neuroleptic or MS therapy
* Requires concurrent AD therapy
* Current psychotic features
* Inadequate trial of therapy at the time of initial screening visit
* History of intolerance to either venlafaxine or lithium
* Unlikely to participate in a 36-week trial
* Presence of apparent secondary gain

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No